2696 Stock Overview
Engages in the research and development of biologic medicines with a focus on oncology, autoimmune diseases, and ophthalmic diseases. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 4/6 |
| Past Performance | 3/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Shanghai Henlius Biotech, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | HK$23.90 |
| 52 Week High | HK$23.95 |
| 52 Week Low | HK$11.60 |
| Beta | 0.83 |
| 1 Month Change | 17.73% |
| 3 Month Change | 3.69% |
| 1 Year Change | 104.27% |
| 3 Year Change | -6.46% |
| 5 Year Change | -40.25% |
| Change since IPO | -51.67% |
Recent News & Updates
Recent updates
Is Shanghai Henlius Biotech (HKG:2696) Using Too Much Debt?
May 25
Shanghai Henlius Biotech, Inc. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next
Mar 25Shanghai Henlius Biotech, Inc.'s (HKG:2696) Price Is Right But Growth Is Lacking
Mar 10Here's Why Shanghai Henlius Biotech (HKG:2696) Is Weighed Down By Its Debt Load
Dec 31The Strong Earnings Posted By Shanghai Henlius Biotech (HKG:2696) Are A Good Indication Of The Strength Of The Business
Nov 25Is Shanghai Henlius Biotech (HKG:2696) Using Too Much Debt?
Sep 18Improved Revenues Required Before Shanghai Henlius Biotech, Inc. (HKG:2696) Shares Find Their Feet
Aug 03Shanghai Henlius Biotech (HKG:2696) Has Debt But No Earnings; Should You Worry?
May 31Need To Know: Analysts Are Much More Bullish On Shanghai Henlius Biotech, Inc. (HKG:2696) Revenues
Apr 06Shareholder Returns
| 2696 | HK Biotechs | HK Market | |
|---|---|---|---|
| 7D | 7.7% | -3.9% | -0.5% |
| 1Y | 104.3% | -5.7% | 19.9% |
Return vs Industry: 2696 exceeded the Hong Kong Biotechs industry which returned -5.7% over the past year.
Return vs Market: 2696 exceeded the Hong Kong Market which returned 19.9% over the past year.
Price Volatility
| 2696 volatility | |
|---|---|
| 2696 Average Weekly Movement | 3.2% |
| Biotechs Industry Average Movement | 11.1% |
| Market Average Movement | 8.8% |
| 10% most volatile stocks in HK Market | 18.6% |
| 10% least volatile stocks in HK Market | 4.1% |
Stable Share Price: 2696 has not had significant price volatility in the past 3 months compared to the Hong Kong market.
Volatility Over Time: 2696's weekly volatility (3%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2010 | 3,546 | Jason Zhu | www.henlius.com |
Shanghai Henlius Biotech, Inc. engages in the research and development of biologic medicines with a focus on oncology, autoimmune diseases, and ophthalmic diseases. It offers HANLIKANG, a rituximab injection for treating non-hodgkin lymphoma, chronic lymphocytic leukemia, and rheumatoid arthritis; HANQUYOU, a trastuzumab injection to treat breast and metastatic breast and gastric cancer; HANDAYUAN, an adalimumab injection for the treatment of rheumatoid arthritis, ankylosing spondylitis, plaque psoriasis, and uveitis; HANBEITAI, a bevacizumab injection to treat metastatic colorectal cancer (mCRC) and recurrent non-small cell lung cancer; and HANSIZHUANG, a serplulimab injection for microsatellite instability-high solid tumors. The company also develops Serplulimab to treat squamous-cell carcinomas, gastric cancer, small cell lung cancer, hepatocellular carcinoma, metastatic colorectal cancer, solid tumors, SCCHN, sqNSCLC, hepatocellular carcinoma, and esophageal squamous cell carcinoma; HLX04-O, an anti-VEGF monoclonal antibody injection for wet age-related macular degeneration; HLX22 to treat breast and metastatic gastric cancer; HLX6018 to treat idiopathic pulmonary fibrosis; HLX07, HLX22, HLX208, HLX60, HLX42, HLX43, HLX53, and HLX51 to treat solid tumors; HLX11 to treat breast cancer; HLX05, a cetuximab injection for mCRC and SCCHN; and HLX14 to treat osteoporosis.
Shanghai Henlius Biotech, Inc. Fundamentals Summary
| 2696 fundamental statistics | |
|---|---|
| Market cap | HK$12.99b |
| Earnings (TTM) | HK$737.84m |
| Revenue (TTM) | HK$6.01b |
17.6x
P/E Ratio2.2x
P/S RatioIs 2696 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 2696 income statement (TTM) | |
|---|---|
| Revenue | CN¥5.64b |
| Cost of Revenue | CN¥1.51b |
| Gross Profit | CN¥4.13b |
| Other Expenses | CN¥3.44b |
| Earnings | CN¥692.34m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 1.27 |
| Gross Margin | 73.23% |
| Net Profit Margin | 12.27% |
| Debt/Equity Ratio | 147.0% |
How did 2696 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/21 21:46 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/06/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Shanghai Henlius Biotech, Inc. is covered by 15 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Yang Huang | BofA Global Research |
| Wangbin Zhou | Citigroup Inc |
| Eva Zhao | Citigroup Inc |